Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
The efficacy of fluconazole, a new bis-triazole antifungal agent, was compared with that of orally administered ketoconazole and parenterally administered amphotericin B against aspergillus and cryptococcus infections in mice. Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B.
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001231:Aspergillus flavus / Q000187:drug effects; D001232:Aspergillus fumigatus / Q000187:drug effects; D001927:Brain Diseases / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole; D007654:Ketoconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D051379:Mice; D009894:Opportunistic Infections / Q000188:drug therapy; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B; D015725:Fluconazole; D007654:Ketoconazole